TGTX vs. DCPH, PTCT, CCXI, SAGE, FGEN, ELAN, INSM, ROIV, LEGN, and ASND
Should you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include Deciphera Pharmaceuticals (DCPH), PTC Therapeutics (PTCT), ChemoCentryx (CCXI), Sage Therapeutics (SAGE), FibroGen (FGEN), Elanco Animal Health (ELAN), Insmed (INSM), Roivant Sciences (ROIV), Legend Biotech (LEGN), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
Deciphera Pharmaceuticals (NASDAQ:DCPH) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.
Deciphera Pharmaceuticals presently has a consensus target price of $24.17, indicating a potential downside of 5.51%. TG Therapeutics has a consensus target price of $29.83, indicating a potential upside of 92.35%. Given Deciphera Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe TG Therapeutics is more favorable than Deciphera Pharmaceuticals.
TG Therapeutics has a net margin of 14.24% compared to TG Therapeutics' net margin of -108.86%. Deciphera Pharmaceuticals' return on equity of 31.34% beat TG Therapeutics' return on equity.
71.0% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 4.7% of Deciphera Pharmaceuticals shares are held by insiders. Comparatively, 9.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
TG Therapeutics received 331 more outperform votes than Deciphera Pharmaceuticals when rated by MarketBeat users. Likewise, 76.77% of users gave TG Therapeutics an outperform vote while only 64.91% of users gave Deciphera Pharmaceuticals an outperform vote.
TG Therapeutics has higher revenue and earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Deciphera Pharmaceuticals had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 4 mentions for Deciphera Pharmaceuticals and 3 mentions for TG Therapeutics. Deciphera Pharmaceuticals' average media sentiment score of 1.17 beat TG Therapeutics' score of 1.13 indicating that TG Therapeutics is being referred to more favorably in the news media.
Deciphera Pharmaceuticals has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500.
Summary
TG Therapeutics beats Deciphera Pharmaceuticals on 15 of the 18 factors compared between the two stocks.
Get TG Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TG Therapeutics Competitors List
Related Companies and Tools
